High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients

The resistance to recombinant human erythropoietin (rHuEpo) therapy in haemodialysis (HD) patients has multifactorial aetiologies: erythropoietin insufficiency, dialysis insufficiency, iron deficiency, and secondary hyperparathyroidism. Angiotensin-converting enzyme (ACE) inhibitors induce anaemia i...

Full description

Saved in:
Bibliographic Details
Published in:Nephrology, dialysis, transplantation dialysis, transplantation, 1998-05, Vol.13 (5), p.1206-1210
Main Authors: ALBITAR, S, GENIN, R, FEN-CHONG, M, SERVEAUX, M.-O, BOURGEON, B
Format: Article
Language:English
Subjects:
Adult
Aged
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Calcium Channel Blockers - therapeutic use
Dose-Response Relationship, Drug
Drug toxicity and drugs side effects treatment
Enalapril - administration & dosage
Enalapril - therapeutic use
Erythropoietin - administration & dosage
Erythropoietin - therapeutic use
Female
Humans
Male
Medical sciences
Middle Aged
Nifedipine - therapeutic use
Pharmacology. Drug treatments
Prospective Studies
Recombinant Proteins
Renal Dialysis
Toxicity: blood
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The resistance to recombinant human erythropoietin (rHuEpo) therapy in haemodialysis (HD) patients has multifactorial aetiologies: erythropoietin insufficiency, dialysis insufficiency, iron deficiency, and secondary hyperparathyroidism. Angiotensin-converting enzyme (ACE) inhibitors induce anaemia in patients with essential hypertension, congestive heart failure, chronic renal insufficiency, and renal transplants. Data exist suggesting that ACE inhibitors impair erythropoiesis in HD patients. Therefore the aim of this study was to investigate the impact of enalapril on rHuEpo requirement. In the present prospective non-randomized study of 12 months, we compared the effects of enalapril and nifedipine on rHuEpo requirement in 40 hypertensive patients receiving rHuEpo for more than 6 months on maintenance haemodialysis. Twenty normotensive rHuEpo-dependent patients served as a control group. All patients with severe hyperparathyroidism or iron deficiency were excluded. The mean (+/- SD) haemoglobin concentration was > 10 g/dl in all groups. The mean weekly rHuEpo dose increased in the enalapril group (P
ISSN:0931-0509
1460-2385
1460-2385
DOI:10.1093/ndt/13.5.1206